BeOne Medicines announced that the U.S. Food and Drug Administration has granted priority review to its supplemental biologics license application for the combination of TEVIMBRA® (tislelizumab) and ZIIHERA® (zanidatamab) with chemotherapy as first‑line therapy for unresectable locally advanced or metastatic HER2‑positive gastric, gastroesophageal junction, or esophageal adenocarcinoma. The priority review designation shortens the FDA’s review timeline to six months, potentially allowing the therapy to reach patients earlier than the standard 10‑month review for supplemental applications.
The decision follows the global Phase 3 HERIZON‑GEA‑01 study, which demonstrated a median overall survival of 26.4 months for the TEVIMBRA‑containing arm versus 19.2 months for the control arm. The study also reported a median progression‑free survival of 12.4 months for the zanidatamab‑containing arms compared with 8.1 months in the control group, underscoring the combination’s ability to extend both survival and disease control.
In addition to priority review, the FDA granted Breakthrough Therapy Designation for this indication, a status that expedites both development and review by providing more frequent interactions with the agency and a rolling review process. The designation signals the FDA’s recognition of the combination’s substantial clinical benefit over existing standards of care.
The HER2‑positive gastric cancer market was valued at approximately USD 1.4 billion in 2025 and is projected to reach USD 1.9 billion by 2035. Trastuzumab (Herceptin) remains the current first‑line standard, but the significant survival advantage shown by the TEVIMBRA+ZIIHERA combination could position it as a new standard of care and potentially displace trastuzumab in this setting.
TEVIMBRA has already received FDA approval for other indications, including HER2‑negative gastric or gastroesophageal junction adenocarcinoma, while ZIIHERA has received accelerated approval in the United States for biliary tract cancer. These prior approvals demonstrate the regulatory track record of both agents and support the likelihood of a smooth review for the new combination.
BeOne’s oncology portfolio includes several other pipeline candidates, reflecting the company’s focus on expanding its presence in high‑growth therapeutic areas. The priority review for the TEVIMBRA+ZIIHERA combination represents a key milestone in the company’s strategy to build a robust commercial pipeline in oncology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.